💊 Get Daily Updates on Generic Entry, Litigation, Biosimilars, and More…
Profile for Karyopharm Therapeutics Inc. (KPTI)
« Back to company indexKPTI Chatter Timeline
Stock Ticker for KPTI
Most Active Tweeters for KPTI
| User | Tweets |
|---|---|
| @Tickeron | 4 |
| @Jarvis_Alerts | 4 |
| @VapzerSignals | 4 |
| @Rajt1111 | 3 |
| @phasefivebot | 3 |
Recent Tweets for KPTI
 |
@formwhisperscom #FWSells $KPTI Mitchener Stephen, SVP, Chief Business Officer of Karyopharm Therapeutics Inc. sold 499 shares on 20… https://t.co/DaVDw8Askm 4:12am |
 |
@InsiderForms $KPTI Insider Mitchener Stephen has Sold 499 Shares. Title :SVP Chief Business Officer Total Cost: $3,338.31 Buy/S… https://t.co/fNuwx5HUEM December 3rd 2021, 11:12pm |
 |
@FlashAlert_me $KPTI [15s. delayed] filed SEC form 4: SVP, Chief Business Officer Mitchener Stephen: Disposed 499 of Common Stock… https://t.co/4cl2sJxAr8 December 3rd 2021, 11:12pm |
 |
@A1Syad $KPTI Awaiting Buy Signal. Stock Trading Ideas by https://t.co/1MjnDHV7ua https://t.co/IFsfYvll8s December 3rd 2021, 6:12pm |
 |
@fda_tracker $KPTI Phase 2 trial w/est Dec completion date NCT03193437: https://t.co/Uz2barqj4u Trial Tracker: https://t.co/aR7q5oJwjn December 3rd 2021, 2:12pm |
 |
@Jarvis_Alerts $KPTI 7.5C Exp:20-May-22 ? ? Total(Day): $66,336 #UnusualActivity Sign-up free for beta ver.:… https://t.co/xU7j3TWJpf December 3rd 2021, 1:12pm |
 |
@TedStamos RT @_B_I_O_T_E_C_H_: $KPTI Selinexor #orphan designation for Treatment of glioblastoma https://t.co/davvtBzXdq December 3rd 2021, 12:12pm |
 |
@Gambiste1 RT @vtmtrading: Compass Pathways appoints Michael Falvey as Chief Financial Officer $CMPS $KPTI December 3rd 2021, 12:12pm |
 |
@vtmtrading Compass Pathways appoints Michael Falvey as Chief Financial Officer $CMPS $KPTI December 3rd 2021, 12:12pm |
 |
@1stOncology #Karyopharm to Host Virtual Investor Day on December 8, 2021 $KPTI https://t.co/RLL2tzTTgR December 3rd 2021, 8:12am |
 |
@_B_I_O_T_E_C_H_ $KPTI Selinexor #orphan designation for Treatment of glioblastoma https://t.co/davvtBzXdq December 3rd 2021, 7:12am |
 |
@pvenkiraju RT @42Stocks: 2021-DEC-02 5:00pm $KPTI #Karyopharm Therapeutics up 8.82% = $46.3 million gain. https://t.co/yq1IFI5G7G (Dec 01) Karyopharm… December 3rd 2021, 4:12am |
|
@pvenkiraju RT @Jarvis_Alerts: $KPTI 7.5C Exp:20-May-22 ? ? Total(Day): $66,336 #UnusualActivity Sign-up free for beta ver.:https://t.co/WnUoHPObTm… December 3rd 2021, 4:12am |
 |
@Rajt1111 @terp2007 @Kevin_W81 My 2 sense is, there is no way $KPTI is not bought by June 22. Too valuable in the hands of big players… December 2nd 2021, 10:12pm |
|
@Jarvis_Alerts $KPTI 7.5C Exp:20-May-22 ? ? Total(Day): $66,336 #UnusualActivity Sign-up free for beta ver.:… https://t.co/RPtK7TY36T December 2nd 2021, 10:12pm |
 |
@42Stocks 2021-DEC-02 5:00pm $KPTI #Karyopharm Therapeutics up 8.82% = $46.3 million gain. https://t.co/yq1IFI5G7G (Dec 01)… https://t.co/2DkHFW3LIX December 2nd 2021, 10:12pm |
 |
@sv_capitalhldg RT @Karyopharm: Karyopharm $KPTI Completes Patient Recruitment in Phase 3 SIENDO Study of Selinexor in Patients with Endometrial Cancer. Le… December 2nd 2021, 3:12pm |
|
@vtmtrading Karyopharm's selinexor granted FDA orphan designation for glioblastoma $KPTI December 2nd 2021, 2:12pm |
 |
@mehabecapital $KPTI @ 6.84 (+4.63%) : Karyopharm completes patient recruitment in late-stage selinexor study in endometrial cancer https://t.co/y06jk0bCp8 December 2nd 2021, 2:12pm |
 |
@StckPro $KPTI NEW ARTICLE : Karyopharm Therapeutics (KPTI) Gets a Buy Rating from H.C. Wainwright https://t.co/KNPmpI2OTr G… https://t.co/qtWxIwvmXi December 2nd 2021, 2:12pm |
 |
@MarketCurrents $KPTI - Karyopharm completes patient recruitment in late-stage selinexor study in endometrial cancer https://t.co/8oa2DVXwR7 December 2nd 2021, 2:12pm |
 |
@MarcJacksonLA $KPTI Karyopharm Completes Patient Recruitment in Phase 3 SIENDO Study of Selinexor in Patients with Endometrial Ca… https://t.co/IcVJJvemEG December 2nd 2021, 2:12pm |
 |
@MLEABUFF Karyopharm $KPTI Completes Patient Recruitment in Phase 3 SIENDO Study of Selinexor in Patients with Endometrial Ca… https://t.co/WzTaqvHNQV December 2nd 2021, 2:12pm |
 |
@Karyopharm Karyopharm $KPTI Completes Patient Recruitment in Phase 3 SIENDO Study of Selinexor in Patients with Endometrial Ca… https://t.co/dILxrTGPnO December 2nd 2021, 1:12pm |
|
@sv_capitalhldg RT @BioStocks: $KPTI Completes Patient Recruitment in Phase 3 SIENDO Study of Selinexor in Patients with Endometrial Cancer. Topline Data b… December 2nd 2021, 1:12pm |
 |
@ChartMill $KPTI was analyzed by 16 analysts. The buy consensus is at 79%. So analysts seem to be mildly confident about $ ...… https://t.co/5KyvHOkFXu December 2nd 2021, 1:12pm |
 |
@GeorgeB14941177 $KPTI Karyopharm Completes Patient Recruitment in Phase 3 SIENDO Study of Selinexor in Patients with Endometrial… https://t.co/fahGrOKoOr December 2nd 2021, 1:12pm |
|
@vtmtrading Karyopharm completes patient recruitment in Phase 3 endometrial cancer study $KPTI December 2nd 2021, 12:12pm |
 |
@bthefirsttoknow First out// $KPTI: Karyopharm Completes Patient Recruitment In Phase 3 SIENDO Study Of Selinexor In Patients With Endometrial December 2nd 2021, 12:12pm |
|
@FlashAlert_me $KPTI [15s. delayed]: Issued Press Release on December 02, 07:00:00: Karyopharm Completes Patient Recruitment in Ph… https://t.co/1BWCk1c345 December 2nd 2021, 12:12pm |
 |
@BioStocks $KPTI Completes Patient Recruitment in Phase 3 SIENDO Study of Selinexor in Patients with Endometrial Cancer. Topli… https://t.co/yRLz0utLe2 December 2nd 2021, 12:12pm |
 |
@FrnkTss $KPTI Karyopharm Completes Patient Recruitment in Phase 3 SIENDO Study of Selinexor in Patients with Endometrial Ca… https://t.co/0CUgKphHuO December 2nd 2021, 12:12pm |
 |
@StockNewsBot2 $KPTI Karyopharm Completes Patient Recruitment in Phase 3 SIENDO Study of Selinexor in Patients with Endometrial Ca… https://t.co/R3Qt4ziV9P December 2nd 2021, 12:12pm |
 |
@quantisnow $KPTI ? Karyopharm Completes Patient Recruitment in Phase 3 SIENDO Study of Selinexor in Patients with Endometrial… https://t.co/1gXl28CUeY December 2nd 2021, 12:12pm |
 |
@stock_titan $KPTI Karyopharm Completes Patient Recruitment in Phase 3 SIENDO Study of Selinexor in Patients with Endometrial Ca… https://t.co/tB3vWuaVme December 2nd 2021, 12:12pm |
 |
@phasefivebot $KPTI Karyopharm Completes Patient Recruitment in Phase 3 SIENDO Study of Selinexor in Patients with Endometrial Ca… https://t.co/DVqqgOyIyB December 2nd 2021, 12:12pm |
 |
@newsfilterio Karyopharm to Host Virtual Investor Day on December 8, 2021 $KPTI https://t.co/Jv6Xqqb1Kc December 2nd 2021, 7:12am |
|
@newsfilterio Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 $KPTI https://t.co/R39P071tVA December 2nd 2021, 1:12am |
 |
@Tickeron $KPTI in Downtrend: RSI indicator exits overbought zone. View odds for this and other indicators:… https://t.co/SIyd0BJqxd December 2nd 2021, 1:12am |
|
@Gambiste1 RT @phasefivebot: $KPTI Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://t.co/u6nUjq7PKA December 1st 2021, 9:12pm |
|
@StockNewsBot2 $KPTI Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://t.co/Q9VtRhRURh December 1st 2021, 9:12pm |
|
@quantisnow $KPTI ? Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)… https://t.co/Zs6uRgIEeH December 1st 2021, 9:12pm |
|
@stock_titan $KPTI Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://t.co/L0i1t95YYQ December 1st 2021, 9:12pm |
|
@phasefivebot $KPTI Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://t.co/u6nUjq7PKA December 1st 2021, 9:12pm |
|
@MarcJacksonLA $KPTI Karyopharm to Host Virtual Investor Day on December 8, 2021 https://t.co/MLlPeImpRW December 1st 2021, 3:12pm |
|
@Rajt1111 @TedStamos @AdamSinger Of these 3, I think $KPTI will bring home not just the bacon but Farm... Massive potential..… https://t.co/tcDyW3IAmE December 1st 2021, 2:12pm |
|
@Karyopharm Karyopharm $KPTI to Host Virtual Investor Day on December 8, 2021 at 10:00am ET. Learn more about participating th… https://t.co/nDBMjrba1b December 1st 2021, 1:12pm |
|
@StockNewsBot2 $KPTI Karyopharm to Host Virtual Investor Day on December 8, 2021 https://t.co/3Bzp944S0N December 1st 2021, 12:12pm |
|
@stock_titan $KPTI Karyopharm to Host Virtual Investor Day on December 8, 2021 https://t.co/lRD1EgKGRF December 1st 2021, 12:12pm |
|
@phasefivebot $KPTI Karyopharm to Host Virtual Investor Day on December 8, 2021 https://t.co/dFbHdqO9aR December 1st 2021, 12:12pm |
DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC
2004 - 2021. All rights reserved.
DrugPatentWatch Video Training
Decision-making for generic drug entry and branded drug lifecycle management
By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
This course answers the following questions to help you adapt:
- ✓ When will key drug patents expire?
- ✓ How can I find, evaluate, and plan for generic market entry opportunities?
- ✓ How can I find proprietary out-of-court settlements and deal terms?